Administration, sample collection, and determination
Contezolid acefosamil (300 mg/vial, as free acid of contezolid acefosamil, batch no.: 20052051), contezolid acefosamil tablets (250 mg/tablet, as free acid of contezolid acefosamil, batch no.: 1286 A17002), 5% glucose injection (250 mL/bag, placebo, batch no.: S2004098), and contezolid acefosamil tablet placebo (batch no.: R134718001) were provided by Shanghai MicuRx Pharmaceutical Co., Ltd.In this study, only blood samples were collected for PK analysis in the 500-mg cohorts. Both blood and urine samples were collected for PK analysis in the other dose cohorts. Detailed plasma sampling points for all cohorts are shown in Table S5. According to the sampling points and results of urinary excretion rate in previous phase I clinical studies of contezolid (